FGFR1 and esophageal squamous cell carcinoma: Furthermore, the FGFR inhibitor AZD 4245 can increase the sensitivity of ESCC with elevated levels of activated FGFR1 to gefitinib, thus suggesting a potential treatment strategy [68].